Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 10 - 18 save search
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Published: 2021-10-18 (Crawled : 19:00) - biospace.com/
PHAT | $9.12 0.66% 0.66% 440K
|
Health Technology
|
| O: 2.92%
H: 0.0%
C: -18.53%
positive results topline phase 3 trial
Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
GERN | $3.57 2.0% 1.96% 6.6M
|
Health Technology
|
| O: 0.71%
H: 3.52%
C: 0.0%
risk phase 3 trial merge syndros enroll
Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis
Published: 2021-10-18 (Crawled : 13:15) - biospace.com/
RDUS | $17.9 1.47% 1.45% 320K
|
Health Technology
|
| O: -1.31%
H: 6.97%
C: 5.98%
positive injection results topline phase 3 osteoporosis abaloparatide tymlos
COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial
Published: 2021-10-18 (Crawled : 07:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 1.3M
|
Health Technology
|
| O: 2.23%
H: 1.9%
C: -1.55%
covid cpg 1018 vaccine phase 3 trial
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint
Published: 2021-10-18 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: -1.45%
treatment lung cancer cancer phase 3
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
Published: 2021-10-17 (Crawled : 00:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: -6.67%
H: 0.7%
C: -8.03%
phase 3 als
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Published: 2021-10-17 (Crawled : 00:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -2.1%
H: 0.03%
C: -3.47%
results topline phase 3 als
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.